Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI

Pediatric Patients Clinical Trial

Official title:

Pharmacokinetics, Safety and Efficacy of a New Gadolinium-based Contrast Agent, P03277, in Pediatric Patients From 2 to 17 Years of Age Undergoing Central Nervous System Contrast-enhanced MRI

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03749252
• Other study ID #: GDX-44-007
• Secondary ID: 2018-001516-30
• Status: Completed
• Phase: Phase 2
• Start date: November 6, 2018
• Est. completion date: August 10, 2020

Study information

• Verified date: May 2022
• Source: Guerbet
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach.

The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of 0.05 mmol/kg body weight (BW) in pediatric population aged from 2 to 17 years undergoing CNS contrast-enhanced MRI (CNS cohort).

Description:

A population PK approach and an age-down staggered approach will be used. Patients will be recruited into 3 predefined age groups: 12-17, 7-11 and 2-6 years. The inclusions will start with the older group (Adolescents, 12-17 years), followed by Preadolescents (7-11 years) and finally Young Children (2-6 years of age).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: August 10, 2020
• Est. primary completion date: December 18, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 2 Years to 17 Years

Eligibility

Inclusion Criteria:

To be included in the study, the patient had to meet all the following criteria:

1. Female or male pediatric patient aged 2 to 17 years,

2. Patient with known or suspected lesion(s) scheduled to undergo routine contrast-enhanced MRI of CNS or of other organs including at least one organ among head and neck, thorax, abdomen, pelvis or musculoskeletal system (including extremities),

3. Patient whose parent(s) or legal guardian having read the information, provided their consent to patient's participation in writing by dating and signing the informed consent prior to any trial related procedure being conducted,

4. Patient with capacity of understanding who received age- and maturity-appropriate information and provided his/her assent to participate in the trial (as required by national regulations),

5. Patient affiliated to national health insurance according to local regulatory requirements.

Non-inclusion Criteria:

Patients could not be included in the study if they presented with one or more of the following non-inclusion criteria:

1. Patient planned for treatment or procedure (e.g., surgery) that would prevent obtaining the required blood samples or performing other trial procedures between the screening visit and up to 1 day after gadopiclenol administration,

2. Patient undergoing treatment or procedure (e.g., diuretics, clinically significant blood loss or blood transfusion) preceding or subsequent to gadopiclenol administration that would alter gadopiclenol PK parameters,

3. Patient with acute or chronic renal insufficiency defined as estimated Glomerular Filtration Rate (eGFR) out of age-adjusted normal ranges (eGFR calculated with bedside Schwartz equation),

4. Patients referred for MR Angiography,

5. Patient with history of bleeding disorder,

6. Patient with known severe liver disease,

7. Patient with known cardiac disease (e.g., heart rhythm anomalies, long QT syndrome),

8. Patient with any clinically significant abnormal 12-lead ECG that in the Investigator's opinion would affect the safety evaluation or place the patient at risk,

9. Patient with electrolyte or fluid imbalance that at Investigator's judgment presents undue risk assessed within 1 month prior to gadopiclenol administration,

10. Patient undergoing a change in chemotherapy within 1 day prior to or 1 day after gadopiclenol administration,

11. Patient who received any other contrast agent for CT and/or MRI within 1 week prior to or 1 week after gadopiclenol administration,

12. Patient with contraindication for MRI such as iron metal implants (e.g., aneurysm clips, pacemaker),

13. Patient with history of anaphylactoid or anaphylactic reaction to any allergen including drugs,

14. Patient with history of hypersensitivity caused by any contrast media / agents (iodinated or gadolinium-based),

15. Patient with known contraindication(s) to the use of any GBCA,

16. Pregnant or breast-feeding female patient (female patient with childbearing potential [who experienced menarche] must have a negative urine pregnancy test within 24 hours prior to gadopiclenol administration and must be using medically approved contraception* if sexually active),

17. Patient with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the patient's safety or her/his ability to participate to the whole trial,

18. Patient unlikely to comply with the protocol, e.g., uncooperative attitude of parent(s) or legal guardian, inability to return for follow-up visits and unlikelihood of completing the trial,

19. Having participated in a clinical trial and having received any investigational product within 7 days prior to gadopiclenol administration or planned during the trial,

20. Patient previously included in this trial,

21. Patient related to the Investigator or any other trial staff or relative directly involved in the trial conduct.

• medically approved contraception methods include: female sterilization, use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception, placement of an Intrauterine Device (IUD) or Intrauterine System (IUS), barrier methods of contraception (condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository).

Related Conditions & MeSH terms

• Central Nervous System Indication
• Pediatric Patients

Intervention

Drug:
• P03277
A dose of 0.05 mmol/kg body weight (0.1 mL/kg body weight) of P03277 will be administered to each patient in a single intravenous injection.

Locations

Country	Name	City	State
Bulgaria	MHAT Central Onco Hospital Ltd	Plovdiv
Bulgaria	Acibadem City Clinic Tokuda Hospital	Sofia
Bulgaria	MHAT Dr. Stoyan Kirkovich	Stara Zagora
Hungary	Semmelweis Egyetem II. sz Gyermekgyogyaszati Klinika	Budapest
Hungary	Markhot Ferenc Oktatokorhaz es Rendelointezet	Eger
Hungary	B.-A.-Z. Megyei Korhaz Gyermek-Egeszsegugyi Kozpont	Miskolc
Poland	Szpital Uniwersytecki nr 1 w Bydgoszczy im. dr Jurasza, Oddzial Kliniczny Chirurgii Ogólnej i Onkologicznej Dzieci i Mlodziezy	Bydgoszcz
Poland	Instytut Centrum Zdrowia Matki Polki	Lódz
Poland	Uniwersytecki Szpital Dzieciecy w Lublinie	Lublin
Poland	Klinika Chirurgii Dzieciecej	Rzeszów
Poland	Instytut "Pomnik -Centrum Zdrowia Dziecka"	Warsaw
Poland	Zaklad Radiologii PediatrycznejSamodzielny Publ. Dzieciecy Szp. Kliniczny w Warszawie	Warsaw
Slovakia	II. Detská klinika SZU, Detská fakultná nemocnica s poliklinikou Banská Bystrica	Banská Bystrica
Slovakia	Klinika detí a dorastu JLF UK a UNM, Univerzitná nemocnica Martin	Martin
Slovakia	Faculty hospital Nitra, Clinic of neonates, children and adolescents	Nitra
Ukraine	Children's City Clinical Hospital	Dnipro

Sponsors (1)

Lead Sponsor	Collaborator
Guerbet

Countries where clinical trial is conducted

Bulgaria,  Hungary,  Poland,  Slovakia,  Ukraine, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Elimination Half-life	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Primary	Total Clearance	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Primary	Central Volume of Distribution	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Primary	Peripheral Volume of Distribution	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Primary	Area Under the Curve	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	4 blood samples per patient were taken post-injection for PK analysis, one within each window: 1 min to 20 min, 30 min to 45 min, 2 to 3 hours and 7 to 8 hours
Primary	Simulated Concentrations 10 Minutes Post-injection	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	10 minutes post-injection
Primary	Simulated Concentrations 20 Minutes Post-injection	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	20 minutes post-injection
Primary	Simulated Concentrations 30 Minutes Post-injection	P03277 pharmacokinetic parameters in plasma were determined from the population PK model.; This outcome was assessed only for the CNS cohort.	30 minutes post-injection